Record growth, eroding margins—the stock's 29% fall reflects the real story
Fujiyama doubled its annual revenue in six months and beat full-year guidance on the top line. But EBITDA and profit margins both fell short, and the market has already priced in the reset.
₹2,652 Cr
=~Full-year FY26; business doubled in one half
17.1% vs 18.9%
−180 bps; vs 18-19% guided range
10.2%
vs 11-13% target; 90 bps below
Negative
₹490 Cr OCF vs ₹661 Cr capex; WC stress
Fujiyama delivered ₹1,307 Cr revenue in Q2, up 130% YoY and already 87% of its full-year 70% growth target for FY27. The topline beat is emphatic. But profit margins compressed simultaneously. Operating margin fell 180 basis points QoQ to 17.1%, landing 120 bps below the prior 18-19% guidance. Net margin hit 10.2%, also short of the 11-13% target. The disparity is striking: revenues grew 130% YoY, EBITDA only 116%. Operating leverage, which should kick in at doubled scale, went the wrong direction.
Where the margin collapse came from
Management blamed three headwinds on the call. First, the Ratlam facility—a new power electronics, cell, and battery manufacturing hub commissioned August 2026—is absorbing overheads ahead of production ramp. Fixed costs are being expensed, not yet spread across output. Second, freight and diesel costs remained elevated. Third, the company deliberately ramped distribution in Tier 2 and Tier 3 cities, incurring one-time brand and marketing spend. These are largely temporary. The real problem is what the call did not resolve: whether the margin recovery is at hand, or structural.
The Q2 FY27 results also absorbed overheads at the Ratlam facility, incurred ahead of the production ramp-up of our recently commissioned panel and inverter division, which contributed to the moderation in EBITDA margin to 17.1% from 18.1% of Q2 FY26.
What changed on this call
Revenue beat, margin miss. Full-year FY27 guidance was set at 70% growth in the prior Q1 call; Q2 is already running at 130% YoY and won't slow to hit 70% for the year without a severe H2 stall. That upside is real, driven by PM Surya Ghar subsidies—the government covered 60+ lakh households in Phase 1, and Fujiyama's 10,200+ channel partners captured a massive share. But management explicitly deferred H2 guidance revision until Q3 results and policy clarity on two binary events: the ALMM List-II mandate (effective Jan 1, 2027, forcing all rooftop solar to use domestically certified cells) and PM Surya Ghar 2.0 approval (battery storage subsidy under consideration). That hedging tone signals conditional confidence, not outright conviction. Inventory and cash flow deteriorated. Inventory spiked ₹320 Cr in the first half to ₹1,230 Cr. Management attributed this to post-Bawal-fire external battery sourcing and ALMM List-II pre-stocking, but working capital days improved only 24 days (123→99) despite 130% revenue growth—the buildup is real. H1 operating cash flow ₹490 Cr was entirely consumed by capex (₹661 Cr) and working capital needs, leaving negative free cash flow. Debt rose from ~₹600 Cr to ₹800 Cr.
Business doubled in 6 months; structural subsidy tailwind confirmed
Revenue growth 130% YoY vs 70% FY27 guidance; trajectory beats forecasts
Integrated manufacturing moat (cell, panel, inverter, battery) hard to replicate
Distribution scale (10,200+ partners, 25 states) and Tier 2-3 brand trust
EBITDA margin fell 180 bps QoQ; below guidance by 120 bps
PAT margin fell to 10.2%, short of 11-13% target
Inventory up ₹320 Cr in H1; only 24-day working capital improvement despite doubled revenue
Free cash flow negative in H1; debt rose ₹200 Cr
Management deferred H2 guidance; contingent on policy clarity (ALMM, Surya Ghar 2.0)
Bawal battery fire loss (₹143 Cr before-tax) one-time drag; insurance claim pending
Ranked risks—what should concern a holder
Policy dependency—ALMM List-II and PM Surya Ghar 2.0 binary outcomes
High50%+ of H1 revenue from Surya Ghar Phase 1; Phase 2.0 (battery subsidy) not approved. ALMM List-II effective Jan 1, 2027 could disrupt supply if DCR cell production doesn't scale. Revenue cliff if either delayed.
Margin compression amid scaled growth—operating leverage absent
HighQ2 OPM 17.1% vs Q1 18.9% (−180 bps) despite 130% YoY revenue growth. Guidance miss (18-19% range) contradicts confidence in margin recovery. If compression is structural, not cyclical, target multiple compresses further.
Inventory buildup and negative free cash flow—working capital stress
HighInventory ₹1,230 Cr (H1 up ₹320 Cr). H1 OCF ₹490 Cr fully consumed by capex and WC. Negative FCF despite doubled revenue suggests buildup may not convert to cash if demand slows or policy changes.
Debt escalation amid capex cycle and negative FCF
MediumNet debt ₹800 Cr (debt/equity 0.55x, manageable now). But rising debt while FCF is negative is unsustainable if growth moderates or H2 margins deteriorate further.
Competitive entry and price deflation—large module makers entering rooftop market
MediumFujiyama has brand and distribution moat, but Canadian Solar, JinkoSolar, Trina entering rooftop. Subsidy pool is finite; if pricing pressure hits, integrated margin advantage erodes.
How the street is positioning
The stock closed at ₹347.05 on the result (as of 2026-11-13). It is down 29.42% from its all-time high of ₹491.7, but up 101.77% off the 52-week low of ₹172. On the intermediate chart, it sits below both the 20-day and 50-day moving averages (₹366.93 and ₹399.29 respectively) but above the 200-day (₹319.36)—a downtrend in progress. RSI at 39.4 signals neither oversold nor overbought; the trend is neutral. Institutional positioning is cooling. FII ownership fell to 1.13% from 1.63% one quarter ago (−50 basis points), and DII also declined to 5.38% from 5.98% (−60 basis points). Promoter stake remains steady at 86.63% with no insider selling signal. The message: foreign and domestic institutions are trimming despite record growth. The 29% drawdown from ATH is the street's verdict on the margin miss and cash flow stress—record revenue is not compensating for the execution gap.
1 · Jan 1, 2027: ALMM List-II mandate
All rooftop solar must use domestically certified (DCR) cells. Market will shift; Fujiyama's 1 GW DCR capacity (1.2 GW TOPCon on track for Q1 FY28) positions it well. Watch for: supply constraints that support pricing, or rapid capacity additions that commoditize prices. This is a 50-50 binary for margin impact.
2 · Q3 FY27 results (Jan 2027): Margin recovery or further compression
Ratlam facility overheads should normalize; inventory should begin to unwind if Surya Ghar continues; freight may moderate. Management will also update H2 trajectory and provide Q4 guidance. The test: do margins return to 18%+ on mid-quarter volumes, or stay compressed? If compressed, structural thesis breaks.
3 · PM Surya Ghar 2.0 approval (date TBD): Battery storage subsidy
Fujiyama has 30-year battery pedigree and 3 GWh lithium-ion capacity. If Surya Ghar 2.0 includes storage subsidy, the company's integrated system (panel + inverter + battery) becomes the obvious play—likely margin lift and incremental revenue stream. If delayed or capped, growth deceleration likely.
Fujiyama Power Systems delivered a quarter of exceptional topline scale—doubled revenue in a year, beat full-year guidance by 2x. But it came with margins compressed 180 basis points QoQ and free cash flow negative in H1. Management is candid on near-term headwinds (Ratlam ramp, inventory, capex) but deferred forward guidance, citing policy contingencies. The market has already priced in the margin miss; the stock is down 29% from ATH despite record growth. Institutions are trimming positions.
Rating: Hold. The long-term structural thesis—PM Surya Ghar on a 67 GW addressable market, integrated manufacturing moat, distribution scale—is intact. But the near-term execution is at risk. The company needs to prove margin recovery in Q3 (back to 18%+ EBITDA) and show positive cash flow generation to justify ownership. Until the debate between temporary Ratlam ramp costs vs. structural margin compression is resolved, the stock deserves to trade at a discount.
The single number to track from here: Q3 EBITDA margin. If it rebounds toward 18%, the thesis recovers and the 29% drawdown becomes tactical. If it stays compressed below 17%, the bull case needs to be rewritten.
Informational and educational content only. Not investment advice.